• Information Technology
  • Human Resources
  • Careers
  • Giving
  • Library
  • Bookstore
  • Active Living
  • Continuing Education
  • Go Dinos
  • UCalgary Maps
  • UCalgary Directory
  • Academic Calendar
My UCalgary
Webmail
D2L
ARCHIBUS
IRISS
  • Faculty of Arts
  • Cumming School of Medicine
  • Faculty of Environmental Design
  • Faculty of Graduate Studies
  • Haskayne School of Business
  • Faculty of Kinesiology
  • Faculty of Law
  • Faculty of Nursing
  • Faculty of Nursing (Qatar)
  • Schulich School of Engineering
  • Faculty of Science
  • Faculty of Social Work
  • Faculty of Veterinary Medicine
  • Werklund School of Education
  • Information TechnologiesIT
  • Human ResourcesHR
  • Careers
  • Giving
  • Library
  • Bookstore
  • Active Living
  • Continuing Education
  • Go Dinos
  • UCalgary Maps
  • UCalgary Directory
  • Academic Calendar
  • Libraries and Cultural Resources
View Item 
  •   PRISM Home
  • Alberta Gambling Research Institute
  • Alberta Gambling Research Institute
  • View Item
  •   PRISM Home
  • Alberta Gambling Research Institute
  • Alberta Gambling Research Institute
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Comparison of clinical efficacy of carbamazepine and haloperidol as adjuncts to lithium in patients with acute manic phase: A double-blind clinical trial

Thumbnail
Download
IJMHA_2003_1(1)_Sabeti_et_al.pdf (113.7Kb)
Author
Sabeti, B.
Amini, H.
Mirsepasi, G. R.
Ghaeli, P.
Goodarzi, R. R.
Accessioned
2010-06-21T19:19:04Z
Available
2010-06-21T19:19:04Z
Issued
2003-09-15
Other
Gambling Literature
Subject
Manic-depressive illness -- Treatment
Type
journal article
Metadata
Show full item record

Abstract
There is abundant evidence that the efficacy of the carbamazepine-lithium combination in acute manic episodes is comparable to that of other custom medications (e.g., a haloperidol-lithium combination). The aim of the current investigation was to compare the clinical efficacy and side effects of lithium combined with carbamazepine versus lithium combined with haloperidol and biperiden in patients with bipolar disorder. In the present study, 24 patients in an acute manic phase were randomly assigned to receive either lithium-carbamazepine (Li-CBZ) or lithium-haloperidol (Li-Hal) combinations for 8 weeks. Clinical (including ESRS, MRS, CBZ side effect profile, and HAM-D) and laboratory measurements were regularly performed on all patients. Both therapeutic regimens were effective in alleviating manic symptoms, whether psychotic features were present or not (p<.001). However, there was a faster response to treatment for the Li-CBZ group compared to the Li-Hal group, as revealed by a lower mean MRS score on day 14 in the former group (p=.018). HAM-D scores revealed significantly better outcomes for the Li-CBZ group. A higher mean HAM-D score on day 56, as well as a higher mean alteration in HAM-D scores throughout the study period, were noted in the Li-Hal group (p=.008 and p=.011, respectively). Dropouts in the Li-Hal group were considerable due to noncompliance resulting from neuroleptic-induced side effects (depressive and extrapyramidal). Similarly, several subjects in the Li-CBZ group had to end the study prematurely as a result of developing side effects for which drug discontinuation is indicated. It may be prudent to reevaluate neuroleptic medications in manic patients, specifically for long-term management.
Refereed
Yes
Copyright © Masood Zangeneh, Editor-in-Chief, International Journal of Mental Health & Addiction
 
Corporate
Tehran University of Medical Sciences, Iran
Faculty
Tehran University of Medical Sciences, Iran
Publisher
eCOMMUNITY: International Journal of Mental Health & Addiction
Uri
http://hdl.handle.net/1880/47854
Collections
  • Alberta Gambling Research Institute

Browse

All of PRISMCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

My Account

LoginRegister

Statistics

Most Popular ItemsStatistics by CountryMost Popular Authors

  • Email
  • SMS
  • 403.220.8895
  • Live Chat

Energize: The Campaign for Eyes High

Privacy Policy
Website feedback

University of Calgary
2500 University Drive NW
Calgary, AB T2N 1N4
CANADA

Copyright © 2017